A Phase 2 Study of CX-8998 in Adolescents and Adults With Idiopathic Generalized Epilepsy With Absence Seizures
Status:
Completed
Trial end date:
2019-03-29
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, open-label study consisting of a screening period of up to 4 weeks and a
4-dose-titration treatment period to a dose of up to 10 mg twice daily (BID) of CX-8998,
followed by a 1-week safety follow-up period after the last dose of study medication.